EPO Patent Bulletin - Organic Chemistry (C07D)

Organic Molecules for Optoelectronic Devices - Samsung Display EP4472973A1

The European Patent Office granted Samsung Display Co., Ltd. Patent EP4472973A1 for organic molecules used in optoelectronic devices. The patent covers compounds classified under C07D 405/14 and H10K with applications in display technology. The designation covers 31 European contracting states including major markets such as DE, FR, GB, IT, and ES.

PSMA Targeting Ligand Compound for Prostate Cancer Diagnosis and Treatment

The European Patent Office published patent application EP4431503A1 filed by Chengdu StarRay Therapeutics Co., Ltd. covering ligand compounds that target PSMA (Prostate-Specific Membrane Antigen) for use in prostate cancer diagnosis and treatment. The application includes claims for chelate compounds and their therapeutic and diagnostic applications. The patent is classified under IPC codes C07D 401/12, C07F 5/00, A61K 51/04, and A61P 35/00, covering 37 designated contracting states.

Novel PARP7 Inhibitor and Use Thereof

The European Patent Office published patent application EP4378938A1 filed by Shanghai Qilu Pharmaceutical Research and Development Centre Ltd., covering a novel PARP7 inhibitor and its therapeutic use. The application was published on April 8, 2026 under IPC classification C07D 403/10 (A61P 35/00 for anticancer indications). The designated states cover all major European Patent Convention contracting states including DE, FR, GB, IT, ES, NL, BE, CH, and others.

EP4426712A1 - Processable Compositions Patent

The European Patent Office published patent application EP4426712A1 filed by Ripple Therapeutics Corporation on April 8, 2026. The patent covers processable compositions including steroidal compounds and heterocyclic derivatives with potential therapeutic applications spanning cardiovascular treatments, glaucoma, and ocular hypertension. The designated contracting states cover all major European Economic Area nations including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS, AND METHODS OF USE THEREOF

The European Patent Office published patent application EP2023216237A1 for JS Innomed Holdings Ltd., covering heterocyclic compounds as kinase inhibitors, compositions, and methods of use. The A1 publication indicates the application has passed formal examination and is now open for opposition. The patent covers compounds classified under IPC C07D 471/04 with therapeutic applications in A61K 31/437 and A61P 35/00 (oncology). The designated states include all current EU member states plus associated countries.

Hinova's Heterocyclic AR Degrader EP4378936A1

The European Patent Office published patent application EP4378936A1, filed by Hinova Pharmaceuticals Inc., covering bifunctional chimeric heterocyclic compounds designed to degrade androgen receptors for therapeutic use. The patent designates 31 EPO member states and classifies under C07D (heterocyclic compounds), A61K (pharmaceutical preparations), and A61P 35/00 (anticancer agents). The filing names 17 inventors and represents a pharmaceutical manufacturer's IP protection strategy for a targeted cancer therapy compound.

PIKFYVE Inhibitor Compounds Patent Application - C07D 487/04

European Patent Office published patent application EP4444316A1 for PIKFYVE inhibitor compounds and pharmaceutical compositions. The application, filed by Kineta, Inc., covers heterocyclic compounds (C07D 487/04) with therapeutic applications including neurological conditions (A61P 25/28). Inventors include Kumaravel, Macdonnell, and Peng. A1 publication indicates the application has entered the European phase and is publicly available for examination.

Fused Benzoisoxazolyl Compounds as KAT6A Inhibitors

The European Patent Office published patent application EP4448109A1 for fused benzoisoxazolyl compounds as KAT6A inhibitors, filed jointly by Aurigene Oncology Limited and Olema Pharmaceuticals, Inc. The invention covers heterocyclic antineoplastic compounds classified under A61P 35/00 and C07D 498/04. The patent is designated for all European Patent Convention contracting states.

Pyrimidine Tricyclic Derivative and Pharmaceutical Application (EP4417613A1)

EPO granted patent EP4417613A1 to CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. The patent covers pyrimidine tricyclic derivatives and their pharmaceutical applications. The patent is designated in multiple contracting states including DE, FR, GB, IT, ES, NL, SE, PL, and other EU member states.

Phenoxy and Benzyloxy Substituted Psychoplastogens and Uses Thereof

The European Patent Office published patent application EP4448531A1 for Delix Therapeutics covering phenoxy and benzyloxy substituted psychoplastogens and their therapeutic uses. The patent application lists designations across 31 European states and territories. The compounds are classified under IPC C07D 487/04 with therapeutic applications including neurological and psychiatric conditions such as anxiety, Alzheimer's disease, and addiction disorders.